A single-arm, Phase II clinical study of camrelizumab combined with anlotinib as second-line treatment for thymic carcinoma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: af96529fe4d44581584313291a74a7cae9ae8518
First added on: Oct 10, 2026